With the improving knowledge of CML and its management, the goals of therapy need to be
revisited to ensure an optimal use of the BCR:: ABL1 TKIs in the frontline and later-line …

Molecularly targeted cancer therapies substantially improve patient outcomes, although the
durability of their effectiveness can be limited. Resistance to these therapies is often related …

Leucine-rich repeat kinase 2 (LRRK2) is the most commonly mutated gene in familial
Parkinson's disease and is also linked to its idiopathic form. LRRK2 has been proposed to …

Chronic myeloid leukemia (CML) is driven by the BCR-ABL1 fusion protein, formed by a
translocation between chromosomes 9 and 22 that creates the Philadelphia chromosome …

Bloodstream infection is a hallmark of sepsis, a medically emergent condition requiring rapid
treatment. However, up-regulation of host defense proteins through Toll-like receptors …

Clinically acquired resistance is a major challenge in cancer therapies with small-molecule
kinase inhibitors (SMKIs). Gatekeeper mutations in the ATP-binding pocket of kinases are …

Abstract Background BCR-ABL1 T315I mutations confer resistance to tyrosine kinase
inhibitors (TKIs) in chronic myeloid leukemia (CML). Olverembatinib is a new potent BCR …

Leucine-rich repeat kinase 2 (LRRK2) is a multifunctional protein that orchestrates a diverse
array of cellular processes, including vesicle transport, autophagy, lysosome degradation …

Discoidin domain receptor (DDR) is a collagen-activated receptor tyrosine kinase that plays
critical roles in regulating essential cellular processes such as morphogenesis …

Current therapeutic approaches for Parkinson's disease (PD) are based around treatments
that alleviate symptoms but do not slow or prevent disease progression. As such, alternative …